Epkinly (epcoritamab-bysp) - Genmab, AbbVie
Epkinly: "Superior PFS with 79% risk reduction"; Follicular lymphoma (Genmab A/S) - Dec 12, 2025 - 2025 R&D Update and ASH Data Review: "Higher response rates" 
P3 data • Follicular Lymphoma • Hematological Malignancies • Oncology
https://ir.genmab.com/static-files/1598fbcc-bb4b-4b87-8d72-0963e30f6a21
 
Dec 12, 2025
 
 
3b8644ce-ba59-4565-9d24-b780c5fae758.png

6b6db28f-8ebb-44ca-ba1e-451e814ce398.png

a878ef6e-6027-4787-a5d4-d8588098b459.png